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Abstract
Background: Patients with hemiplegic migraine (HM) may sometimes develop progressive neurological deterioration of
which the pathophysiology is unknown.
Patient: We report a 16-year clinical and neuroradiological follow-up of a patient carrying a de novo p.Ser218Leu
CACNA1A HM mutation who had nine severe HM attacks associated with seizures and decreased consciousness between
the ages of 3 and 12 years.
Results: Repeated ictal and postictal neuroimaging revealed cytotoxic oedema during severe HM attacks in the symp-
tomatic hemisphere, which later showed atrophic changes. In addition, progressive cerebellar atrophy was observed.
Brain atrophy halted after cessation of severe attacks, possibly due to prophylactic treatment with flunarizine and sodium
valproate.
Conclusion: Severe HM attacks may result in brain atrophy and prophylactic treatment of these attacks might be
needed in an early stage of disease to prevent permanent brain damage.
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Introduction
Familial (FHM) and sporadic hemiplegic migraine
(SHM) are rare subtypes of migraine characterised by
transient motor weakness during the aura phase and
caused by mutations in CACNA1A, ATP1A2 or
SCN1A (1). Here, we report a unique 16-year follow-up
of a SHM patient. Repeated ictal and postictal neuroi-
maging revealed cytotoxic oedema during attacks lead-
ing to brain atrophy which halted after cessation of
severe HM attacks.
Case report
This currently 19-year-old woman was diagnosed with
SHM due to a de novo p.Ser218Leu CACNA1A
mutation during childhood. She was also diagnosed
with Brugada syndrome, an inherited cardiac disorder.
Some features of this patient were previously briefly
reported by our group (2). Apart from ‘early seizures
and cerebral oedema after trivial head trauma’
(ESCEATHT) the p.Ser218Leu CACNA1A mutation
has been associated with hemiconvulsion–hemiplegia–
epilepsy syndrome (2,3). The comprehensive phenotype
thus illustrates the often-described co-occurrence of
SHM/FHM and epilepsy (4). Shortly after birth, our
SHM patient developed apnoea but after resuscitation
and artificial ventilation she breathed spontaneously.
She showcased impaired psychomotor development
and cerebellar ataxia from infancy. Upon first hospital
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Figure 1. At the age of three years, during a hemiplegic migraine attack, FLAIR (a) and T2-weighted (T2W) images (b) showed right
hemispheric diffuse cortical swelling. Diffusion-weighted imaging (DWI) (c) showed diffusion restriction, most notable in the right
parieto-occipital region (arrows). Mild cerebellar atrophy was present, as illustrated on the sagittal T2W image (d). At the age of ten
years, interictal axial T1-weighted (T1W) (e) and T2W images (f) showed marked cortical atrophy in the right parieto-occipital
regions, corresponding with the previous area of diffusion restriction (c). Progressive cerebellar atrophy was observed on sagittal
T1W images (g, h). At the age of 12 years, during a hemiplegic migraine attack, coronal FLAIR (i) and axial T2W images (j) showed
diffuse cortical swelling of the whole left hemisphere (arrow) with slight diffusion restriction on DWI and apparent diffusion coefficient
images (k, l). Follow-up MRI at 13 years showed progressive cerebral and cerebellar atrophy on the coronal FLAIR (m), axial T2W (n)
and sagittal T1W images (o, p). After the start of prophylactic medication and subsequent ceasing of severe hemiplegic attacks, follow-
up MRI at 19 years revealed no evident progression of cerebellar and cerebral atrophy as visible on coronal T1W (q), axial T2W (r)
and sagittal T1W images (s, t).
1200 Cephalalgia 38(6)
admission at the age of three years, she showed loss of
consciousness and left-sided hemiconvulsions for 2 h,
starting 30min after minor head trauma. After two
days, brain MRI revealed right hemispheric cortical
oedema with cytotoxic oedema, most notable in the
right parieto-occipital region. Mild cerebellar atrophy
was also evident (Fig. 1a–d). The attack was followed
by a week-long left-sided neglect and hemiparesis. At
the age of ten years, interictal brain MRI displayed
marked cortical atrophy corresponding to the areas of
cytotoxic oedema from when she was three years old
(Fig. 1e–h). At the age of 12 years, she was admitted
with decreased consciousness, right hemiparesis, fever
and vomiting. Brain MRI revealed left hemispheric cor-
tical oedema with cytotoxic oedema (Fig. 1i–l). Nine
months later, she suffered a similar attack with
decreased consciousness, left deviation of eyes and
head, and a right hemiparesis. She had a fever
(38.7C) and an EEG showed asymmetric slow high-
voltage activity over the entire left hemisphere. Some
abnormalities suspect for epileptic discharges were
noted over the right hemisphere. During hospital
admission, she had several short-lasting epileptic seiz-
ures. A follow-up EEG several days later showed an
improved pattern and no signs of epilepsy. Due to dif-
ficulties swallowing and fear of respiratory failure, she
was shortly admitted to the intensive care unit. She
remained in a state of decreased consciousness for
nine days and was discharged from hospital after
12 days. Four months later, mild left-hemispheric cor-
tical atrophy was observed on interictal brain MRI,
corresponding to the areas of cytotoxic oedema
during the previous attack, as well as progressive
right-hemispheric and cerebellar atrophy (Fig. 1m–p).
In total, between the ages of three and 12 years, she
suffered nine of these severe HM attacks. After each
severe attack, her psychomotor skills deteriorated,
improving only slowly and incompletely. Since the
age of 12 years, she has been treated with flunarizine
and sodium valproate, after which severe attacks
halted. At 16 years, her IQ was scored below 50.
Interictal examination, at 18 years, revealed gaze-
evoked nystagmus, mild ataxia in both arms and ataxic
gait but no motor weakness. She continues having mild
attacks during which her arm or leg feels ‘strange’ and
some motor weakness appears to be present which
resolves completely within hours. She presented with
further deterioration of psychomotor skills at the age of
19 years. However, interictal brain MRI revealed no pro-
gression of cerebral and cerebellar atrophy compared
with the interictal MRI at 13 years (Fig. 1q–t).
Discussion
In our patient, progression of brain atrophy halted
after cessation of severe HM attacks, as was reported
in an HM patient with a p.Thr666Met CACNA1A
mutation (5). Cytotoxic oedema during HM attacks is
thought to be attributable to enhanced susceptibility to
cortical spreading depression (CSD), the electrophysio-
logical correlate of migraine aura, which may be
accompanied by transient neuronal swelling (6). The
p.Ser218Leu CACNA1A mutation particularly
enhances susceptibility to CSD (6). As a result, even
weak stimuli may trigger repetitive and prolonged
CSDs associated with cerebral oedema. This is in line
with the severe phenotype of patients with this specific
mutation, with severe, sometimes fatal, cerebral
oedema (2). Repetitive CSDs may eventually result in
neuronal cell death (7), which is illustrated by the severe
brain atrophy in our case. In contrast, cerebellar
atrophy in HM is thought to be caused by a different
mechanism in which a direct effect on Purkinje cells
causes neuronal cell loss (8).
A limitation of our report is that effects of the
prophylactic treatment are difficult to assess due to
several reasons: (i) we describe a single case; (ii) the
low attack frequency in our patient; (iii) spontaneous
reduction in attack frequency may occur with age in
(hemiplegic) migraine (9,10), although usually not at
such a young age. However, since treatment with flu-
narizine and sodium valproate, no severe HM attack
has occurred and the cortical atrophy seems not to have
progressed. The clinical psychomotor deterioration at
the age of 19 years in our patient could not be related to
progression of cerebral atrophy and thus may have
been due to other unknown chronic mechanisms in
HM. Furthermore, cognitive complaints can occur
with the use of sodium valproate (11).
This unique case illustrates development of second-
ary cortical atrophy in previously affected brain areas
during severe HM attacks and suggests that adequate
prophylaxis may be critical to prevent permanent brain
damage in HM patients.
Clinical implications
. Severe hemiplegic migraine attacks may result in brain atrophy.
. Adequate prophylaxis may be critical to prevent permanent brain damage in HM patients.
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